Led · Grant · Mar 2026

Seaport Therapeutics develops medicines that use its Glyph platform to route drugs through the gut’s lymphatic vessels, enhancing bioavailability while limiting systemic exposure. The company’s lead non-CNS program is GlyphCele, an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib designed to restore gut lymphatic function implicated in metabolic diseases and pancreatic cancer. Preclinical studies show GlyphCele can repair lymphatic damage, improve metabolic markers, and potentially suppress tumor spread by delivering therapy directly to lymphatic tissue. While Seaport’s core pipeline remains focused on neuropsychiatric medicines, the firm is expanding the platform’s reach into metabolic and oncologic indications through external, non-dilutive funding. There are currently no approved oral drugs that directly target the lymphatic system, positioning Seaport to pioneer a new disease-modifying approach. The company recently secured up to $15 million in ARPA-H support, providing runway for continued preclinical and early clinical development; no revenue, user, or commercialization metrics were disclosed in the article.

Led · Grant · Oct 2025

Owlstone Medical is building a breathalyser-style diagnostic platform that captures and analyses volatile organic compounds (VOCs) in exhaled breath to identify disease-specific biomarkers. Its core Breath Biopsy® platform is powered by the ReCIVA® Breath Sampler and supported by proprietary FAIMS microchip chemical sensor technology and EVOC® probes. The company’s vision is to save 100,000 lives and cut healthcare costs by $1.5 billion through earlier, more precise detection and treatment. Owlstone’s technology is being expanded to cover respiratory and liver diseases, digestive health disorders, and, most prominently, cancer. A newly awarded ARPA-H contract of up to $49.1 million will finance development of a synthetic-sensor multi-cancer early-detection (MCED) test that can identify more than 30 solid tumours at Stage I using breath and urine samples. The program will deliver single-use inhalers containing pan-cancer and tumour-specific sensors, with results uploaded directly to electronic health records for rapid clinical review. Partnerships with MIT, Boston University, Georgia Tech Research Corporation, Qurin B.V., and Planned Systems International will help advance this low-cost, home-usable diagnostic toward commercial deployment.

Led · Grant · Feb 2025

Homeward builds care delivery solutions and a navigation platform that uses advanced analytics to connect rural members to appropriate care and local resources. The company takes financial accountability for clinical outcomes and total cost of care across rural counties and supplements local clinical capacity with employed care teams. As a public benefit corporation and B Corp™ certified company, Homeward partners with payers, providers, and community organizations to strengthen local healthcare ecosystems. It has launched an Advanced Research Program to adapt health technologies for rural needs and will use research partnerships to test scalable models. Homeward was selected to receive up to $12 million in research funding from ARPA‑H’s PARADIGM program to advance mobile, distributed clinical services such as perinatal care and advanced wound care. Homeward deploys an integrated care model combining mobile clinics, in-home visits, virtual care, and cellular-based remote monitoring to connect rural Medicare-eligible beneficiaries with multidisciplinary care teams. The company focuses on improving access, coordinating with regional health systems and local physicians, and triaging services to appropriate in-person care when needed. Homeward supports Medicare-eligible beneficiaries and says it takes full risk for the cost of care of its members under value-based arrangements. The company highlights a target market that encompasses roughly 60 million Americans living in rural communities and notes that about 90% of rural Medicare-eligible beneficiaries are covered by seven payers. Homeward plans to use new funding to accelerate expansion into additional states through value-based contracts with health plans and to scale its on-the-ground and virtual specialty-capable care teams. It also announced a value-based care partnership with Priority Health to deliver comprehensive care to Medicare Advantage members in rural Michigan. Homeward launched with $20 million in funding to expand access to healthcare in rural communities. The company deploys a hybrid care model that combines virtual care, mobile in-person care units, and in-home remote patient monitoring that uses cellular-based devices to capture biometric data. Its multidisciplinary teams provide virtual and on-the-ground services designed to augment local primary care physicians and hospitals. Homeward plans to accelerate deployments into key rural markets, build out its team, and coordinate entry into early markets ahead of service rollouts planned for summer 2022. The company intends to partner with regional Medicare Advantage plans to reach members and emphasizes value-based care and prevention through continuous monitoring. Several members of the leadership team are former Livongo executives, including CEO Dr. Jennifer Schneider, co-founder and president Amar Kendale, COO Dr. Bimal Shah, and chief administrative officer Brian Vandenberg.

Led · Grant · Sep 2024

Cellino Biotech is building an ultra-scalable, autonomous, high-precision biomanufacturing platform to produce personalized regenerative cells and tissues. Its NEBULA program focuses on a cassette-based approach intended to scale production of induced pluripotent stem cells (iPSCs) at hospitals nationwide. The company combines AI-guided, laser-based cell management and a proprietary optical bioprocess to automate manual, artisanal steps and reduce variability. Cellino aims to lower costs for patient-specific regenerative medicines and improve access and equity by minimizing immune-related complications. NEBULA targets deployment to accelerate therapies for conditions including Parkinson’s, heart disease, spinal cord injury, age-related macular degeneration, and diabetes. The company is based in Cambridge, Mass. Cellino Bio is building an autonomous, closed-loop platform to manufacture induced pluripotent stem cells (iPSCs) at scale. Its core technologies combine a laser-based cell-editing system to remove or modify cells with machine learning algorithms that identify subpar cells. The company aims to create a fully autonomous human cell foundry by 2025 to address manufacturing bottlenecks in regenerative medicine. Cellino is collaborating with Kapil Bharti’s team at the National Eye Institute and will manufacture iPSCs for an upcoming clinical trial intended to transplant personalized iPSCs into patient retinas, with the longer-term goal of an iPSC-derived retinal pigment epithelium product. Post‑raise, Cellino plans to expand hiring to boost its machine learning capacity and to build a comparability dataset to show its cells match clinical-grade lines in safety and quality. Financially, the company announced an $80M Series A and has $96M in total funding to date. Cellino develops an automated platform that combines AI, machine learning, hardware, software and laser-based cellular editing to identify and remove low-quality cells in stem-cell manufacturing. The system trains on large datasets and uses morphology and fluorescence-based assays to classify cells, then targets unwanted cells with a laser that creates cavitation bubbles at ~5-micron resolution. That approach yields throughput of about 5,000 cells per minute and aims to raise usable cell yields from current manual rates (~10–20%) to at least 80% within three years. The company projects its automation could cut per-patient manufacturing costs from nearly $1M for outsourced production down toward the tens of thousands over time. Founded by scientists with backgrounds in physics, stem cell biology and machine learning, leadership includes CEO Nabiha Saklayen (who patented cellular laser editing at Harvard), co-founder Marinna Madrid and CTO Mattias Wagner. Cellino is collaborating with the NIH on compatibility studies and has presented at TechCrunch Disrupt to source talent and promote democratization of cell therapies.

Led · Equity · Mar 2024

Cambridge-based Thymmune Therapeutics uses machine-learning-guided protocols to convert induced pluripotent stem cells into thymic epithelial and stromal cells that are formulated for direct intramuscular injection, where they self-assemble into thymus-like tissue capable of generating new naïve T cells. Founded by Dr. Stan Wang and backed scientifically by Harvard geneticist George Church, the company’s first clinical focus is congenital athymia, a rare, fatal disorder in which children are born without a thymus. Longer term, Thymmune aims to treat thymic damage caused by chemotherapy, radiation, transplantation, and normal aging, ultimately positioning the therapy as a broad immune-rejuvenation product for the general population. Preclinical studies in humanized animal models have already demonstrated local formation of functional thymic tissue and new T-cell production. Financially, Thymmune is pre-revenue and has secured $37 million in non-dilutive ARPA-H project funding to advance toward IND-enabling work and first-in-human trials. The company is now scaling GMP-grade manufacturing and assembling regulatory packages to enter the clinic within the next few years.